Celestia S. Higano, Paul F. Schellhammer, Eric J. Small, Patrick A. Burch, John Nemunaitis, Lianng Yuh, Nicole Provost and Mark W. Frohlich Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer Cancer 115
Article first published online: 17 JUN 2009 | DOI: 10.1002/cncr.24429
The integrated results of 2 randomized studies demonstrate a survival benefit for patients treated with sipuleucel-T compared with those treated with placebo. The generally modest toxicity profile, coupled with the survival benefit, suggests a favorable risk-benefit ratio for sipuleucel-T in patients with advanced prostate cancer.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field